WallStreetZenWallStreetZen

NASDAQ: RCEL
Avita Medical Inc Stock

$8.57-0.41 (-4.57%)
Updated Apr 24, 2024
RCEL Price
$8.57
Fair Value Price
N/A
Market Cap
$220.31M
52 Week Low
$8.46
52 Week High
$21.70
P/E
-6.12x
P/B
4.49x
P/S
6.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$51.57M
Earnings
-$35.38M
Gross Margin
84.9%
Operating Margin
-66.26%
Profit Margin
-68.6%
Debt to Equity
1.26
Operating Cash Flow
-$38M
Beta
1.51
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RCEL Overview

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RCEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RCEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RCEL is poor value based on its book value relative to its share price (4.49x), compared to the US Medical Devices industry average (3.73x)
P/B vs Industry Valuation
RCEL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RCEL due diligence checks available for Premium users.

Be the first to know about important RCEL news, forecast changes, insider trades & much more!

RCEL News

Valuation

RCEL fair value

Fair Value of RCEL stock based on Discounted Cash Flow (DCF)
Price
$8.57
Fair Value
$16.92
Undervalued by
49.36%
RCEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RCEL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.12x
Industry
30.46x
Market
41.27x

RCEL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.49x
Industry
3.73x
RCEL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RCEL's financial health

Profit margin

Revenue
$14.3M
Net Income
-$7.1M
Profit Margin
-49.6%
RCEL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RCEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$111.6M
Liabilities
$61.9M
Debt to equity
1.26
RCEL's short-term assets ($104.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RCEL's short-term assets ($104.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.9M
Investing
-$57.3M
Financing
$39.4M
RCEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RCEL vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
RCEL$220.31M-4.57%-6.12x4.49x
ARAY$218.17M-0.90%-14.67x4.58x
SENS$229.78M+0.70%-3.94x6.42x
SMLR$187.17M-1.73%8.70x2.61x
MASS$184.95M+1.08%-4.97x1.12x

Avita Medical Stock FAQ

What is Avita Medical's quote symbol?

(NASDAQ: RCEL) Avita Medical trades on the NASDAQ under the ticker symbol RCEL. Avita Medical stock quotes can also be displayed as NASDAQ: RCEL.

If you're new to stock investing, here's how to buy Avita Medical stock.

What is the 52 week high and low for Avita Medical (NASDAQ: RCEL)?

(NASDAQ: RCEL) Avita Medical's 52-week high was $21.70, and its 52-week low was $8.46. It is currently -60.51% from its 52-week high and 1.3% from its 52-week low.

How much is Avita Medical stock worth today?

(NASDAQ: RCEL) Avita Medical currently has 25,706,662 outstanding shares. With Avita Medical stock trading at $8.57 per share, the total value of Avita Medical stock (market capitalization) is $220.31M.

Avita Medical stock was originally listed at a price of $35.60 in Oct 2, 2019. If you had invested in Avita Medical stock at $35.60, your return over the last 4 years would have been -75.93%, for an annualized return of -29.95% (not including any dividends or dividend reinvestments).

How much is Avita Medical's stock price per share?

(NASDAQ: RCEL) Avita Medical stock price per share is $8.57 today (as of Apr 24, 2024).

What is Avita Medical's Market Cap?

(NASDAQ: RCEL) Avita Medical's market cap is $220.31M, as of Apr 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Avita Medical's market cap is calculated by multiplying RCEL's current stock price of $8.57 by RCEL's total outstanding shares of 25,706,662.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.